NIO's Chip Subsidiary SiRider Pivots to Full-Domain AI Platform; Morgan Stanley Maintains Overweight
Alina Collins
NIO's chip subsidiary GeniTech debuted as a standalone brand at WAIC, repositioning from an in-house driving chip supplier to a full-spectrum AI silicon platform; Morgan Stanley maintains Overweight with a HK$58 target — roughly 48% upside.
What is GeniTech actually trying to become?
At WAIC, GeniTech announced coverage across three domains: assisted driving, embodied intelligence, and agentic inference — calling itself China's only chipmaker spanning all three.
This means → it is no longer just "NIO's internal chip team." It aims to be an externally open AI chip platform.
In plain terms = it used to make chips only for NIO's own cars. Now it wants to sell silicon to robotics, autonomous logistics, and high-compute edge devices — the addressable customer base jumps from one automaker to the entire AI hardware market.
Where does the product lineup stand today?
The core product is the NX9031 series, built on a 5 nm automotive-grade process. The high-end NX9031X targets assisted driving and ships in every NIO and Onvo model, with cumulative shipments exceeding 300,000 units.
The mid-tier NX9031U delivers up to 800 TOPS equivalent compute under air cooling, powering the "RuiDong" robotics perception-planning platform.
This means → the same chip fits in a car and in a robot — one piece of silicon, multiple end markets. That is the foundation of a platform play.
Why does Morgan Stanley like this pivot?
Analyst Tim Hsiao's team argues GeniTech is shifting NIO's equity narrative from "cash-burning EV maker" to "vertically integrated AI chip platform."
The key logic: migrating chips from driving into adjacent workloads — humanoid robots, unmanned logistics, high-compute terminals — widens the addressable market and adds upside to the growth story.
In plain terms = if NIO only sells cars, the ceiling is car sales. If its chips can serve the broader AI hardware industry, the story's ceiling rises dramatically.
Where does the money come from, and how do costs come down?
Since its June 2025 spin-off, GeniTech has attracted nearly RMB 3 billion in outside funding; its February fundraise set a post-money valuation of roughly RMB 8.3 billion. NIO retains about 63% ownership.
This means → external capital shares the R&D burden, easing NIO's cash pressure.
On costs, a single NX9031 matches the compute of four Nvidia Orin processors. Every additional unit shipped spreads fixed R&D costs over a larger base. GeniTech began licensing NX9031 technology to third-party chip vendors in late 2025, adding a royalty revenue stream.
What do the valuation and financial forecasts look like?
Morgan Stanley maintains Overweight on NIO's Hong Kong listing with a HK$58 price target — about 48% above the HK$39.26 close.
Forecast: 2026 revenue of roughly RMB 128.6 billion, EBITDA turning positive at about RMB 2.6 billion, net loss narrowing to roughly RMB 3.3 billion; net profit breakeven is expected in 2027.
The base case target is HK$50, bull case HK$109, bear case HK$21. This reflects enormous valuation elasticity — whether GeniTech keeps attracting outside capital and whether scale economics materialise on schedule are the pivotal tests of this thesis.
Content is for reference only, not financial advice.